Plain-English translation of NCT07018518 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a combination of two treatments for advanced hepatocellular carcinoma (liver cancer) that has stopped responding to standard therapies. The first treatment is PIN (Pyroptosis-inducible Newcastle Disease Oncolytic Virus)—a specially engineered virus designed to infect and kill cancer cells while leaving healthy cells alone. The second is an anti-PD1 immunotherapy drug that helps your immune system fight the cancer. Together, researchers believe these treatments can work better than either one alone.
Advanced liver cancer often stops responding to current standard treatments, leaving patients with very few options and a poor outlook. This medication and similar approaches show promise in early research, but doctors need to test whether combining this new virus therapy with immunotherapy is safe and effective in real patients.
You likely qualify if…
You likely don't qualify if…
You will receive 8 cycles of combined treatment, with the virus injected directly into accessible tumors and the immunotherapy drug given intravenously. After these initial cycles, if your cancer responds well but some tumors remain, you will continue with the immunotherapy alone every 3 weeks for up to 2 years. Throughout the trial, you will have regular blood tests, imaging scans, and possibly tumor biopsies to monitor how you are responding. The trial lasts up to 2 years, with clinic visits occurring regularly during active treatment.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
China